Tumor-Infiltrating Lymphocytes and Interleukin-2 in Melanomas
- 25 May 1989
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 320 (21) , 1418-1419
- https://doi.org/10.1056/nejm198905253202115
Abstract
Correspondence from The New England Journal of Medicine — Tumor-Infiltrating Lymphocytes and Interleukin-2 in MelanomasKeywords
This publication has 7 references indexed in Scilit:
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating LymphocytesJNCI Journal of the National Cancer Institute, 1988
- Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1JNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985